Agonist News and Research

RSS

Shire's INTUNIV (Guanfacine) approved by the FDA for treatment of Attention-Deficit/Hyperactivity Disorder

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV- (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.

4 Sep 2009

P2Y2 to be included in the intellectual property sale auction

Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that the P2Y2 Gastrointestinal Early Development Candidate Program will be part of the intellectual property offered for sale at the September 30, 2009 auction.

3 Sep 2009

Ono Pharmaceutical secures exclusive rights to develop and commercialize asimadoline in Japan

Tioga Pharmaceuticals, Inc. and Ono Pharmaceutical Co, Ltd. Osaka, Japan today announced an exclusive license agreement under which Ono has licensed rights to develop and commercialize asimadoline in Japan, South Korea and Taiwan. Tioga retains all other rights to asimadoline.

2 Sep 2009

Higher education levels associated with an earlier need for symptomatic treatment of Parkinson's disease

Individuals who have higher levels of education and who are more impaired by Parkinson's disease appear to require treatment for their symptoms earlier than do other patients, according to a report posted online today that will appear in the September print issue of Archives of Neurology, one of the JAMA/Archives journals.

2 Sep 2009

Paper discussing the mechanism of the selective TGR5 agonist INT-777 published in Cell Metabolism

Bile acids are known to be key regulators of lipid, glucose and overall energy metabolism. Bile acid activation of the G protein-coupled receptor TGR5 has been shown to induce energy expenditure in muscle and brown fat, thereby conferring resistance to weight gain.

2 Sep 2009

Forest Laboratories announces phase 3 trial results for roflumilast

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer and Nycomed, a privately owned pharmaceutical company, today announced that results of four phase III trials have been published in the prestigious peer-reviewed medical journal The Lancet showing that roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, improved lung function and reduced exacerbations in patients with moderate to severe COPD.

28 Aug 2009

Comprehensive review on the pharmacology of sigma receptors published in Journal of Pharmacology Therapeutics

Anavex Life Sciences Corp. ("ANAVEX" or the "Company") reports the publication of a comprehensive review of the pharmacology of sigma receptors and their possible clinical application in the peer-reviewed Journal of Pharmacology Therapeutics.

28 Aug 2009

European Medicines Agency validates Schering-Plough's MAA for nomegestrol acetate/17 beta-estradiol

Schering-Plough Corporation, (NYSE: SGP), today announced that the European Medicines Agency (EMEA) has validated (accepted for review) the company's Marketing Authorization Application (MAA) for a fixed-dose combination of mometasone furoate and formoterol fumarate for the maintenance treatment of asthma in patients 12 years of age and older.

27 Aug 2009

Study reveals that asthma patients fare better by taking oral controllers than inhaled corticosteroids

Mayo Clinic Proceedings published a peer-reviewed comparative effectiveness study performed by HealthCore, Inc. in its August edition. The study demonstrated that asthma patients in general had better clinical outcomes with oral controllers than inhaled corticosteroids.

27 Aug 2009

Study suspects involvement of PPAR-γ in gastric carcinogenesis

Recently, the potential of PPAR-γ as a target for the prevention and treatment of cancer has been widely studied. However, the potential therapeutic role of PPAR-γ agonists has been questioned, based on contradictory results. Studies using animal models of colon cancer found that PPAR-γ agonists increased the development of colon tumors.

27 Aug 2009

EPIX Pharmaceuticals' PRX-00023 Therapeutics CNS program in Phase 2B/3 offered for auction sale

Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that the PRX-00023 Therapeutics Program in Phase 2b/3 will be part of the intellectual property offered for sale at the September 30, 2009 auction.

26 Aug 2009

HealthCore study reports that oral controllers provide better clinical outcomes for asthma patients

Mayo Clinic Proceedings published a peer-reviewed comparative effectiveness study performed by HealthCore, Inc. in its August edition. The study demonstrated that in general had better clinical outcomes with oral controllers than inhaled corticosteroids.

26 Aug 2009

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Neurogen Corporation (NASDAQ:NRGN) announced today they have entered into a definitive merger agreement under which Ligand will acquire Neurogen. Under the transaction, Neurogen stockholders will receive an estimated $11 million in Ligand common stock and will be granted Contingent Value Rights (“CVRs”) under four CVR agreements.

25 Aug 2009

Dynavax announces European development strategy for investigational adult hepatitis B vaccine in Europe

Dynavax Technologies Corporation (Nasdaq:DVAX) today announced that it has met with the European Medicines Evaluation Agency (EMEA) to discuss its plans for continued clinical development of HEPLISAVTM Phase 3 investigational adult hepatitis B vaccine in Europe.

12 Aug 2009

Tiotropium - corticosteroid combination improves lung disease survival

Sufferers of chronic obstructive pulmonary disease have a greater chance of survival when treated with a combination of drugs that includes tiotropium, according to research at the University of Illinois at Chicago.

12 Aug 2009

Discovery of new molecular pathway for targeting cancer

A UCLA study has identified a way to turn off a key signaling pathway involved in physiological processes that can also stimulate the development of cancer and other diseases. The findings may lead to new treatments and targeted drugs using this approach.

20 Jul 2009

Discovery of genetic markers to help fight diabetes

Translational Genomics Research Institute (TGen) scientists have identified five genetic biomarkers that could help lead to improved treatments, with fewer side-effects, for patients with diabetes.

17 Jun 2009

Being overweight or obese does not worsen asthma, but may reduce response to medications

Being overweight or obese does not make asthma worse in patients with mild and moderate forms of the disease, according to a study by National Jewish Health researchers, although it may reduce the response to medications.

3 Jun 2009

Merck Serono starts second phase III trial of Safinamide in advanced Parkinson's

Merck Serono announced today the initiation of the SETTLE study. This study will evaluate the efficacy and safety of a dose range of safinamide (50-100 mg once daily) as add-on therapy to a stable dose of levodopa, in mid- to late-stage Parkinson's disease patients with motor fluctuations compared to placebo.

7 May 2009

Ferring Pharmaceuticals launches new trial of Degarelix for intermittent androgen deprivation therapy

Ferring Pharmaceuticals has announced the launch of a Phase IIIB clinical trial of degarelix for injection, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone sensitive advanced prostate cancer.

27 Apr 2009

Agonist News and Research

Shire's INTUNIV (Guanfacine) approved by the FDA for treatment of Attention-Deficit/Hyperactivity Disorder

P2Y2 to be included in the intellectual property sale auction

Ono Pharmaceutical secures exclusive rights to develop and commercialize asimadoline in Japan

Higher education levels associated with an earlier need for symptomatic treatment of Parkinson's disease

Paper discussing the mechanism of the selective TGR5 agonist INT-777 published in Cell Metabolism

Forest Laboratories announces phase 3 trial results for roflumilast

Comprehensive review on the pharmacology of sigma receptors published in Journal of Pharmacology Therapeutics

European Medicines Agency validates Schering-Plough's MAA for nomegestrol acetate/17 beta-estradiol

Study reveals that asthma patients fare better by taking oral controllers than inhaled corticosteroids

Study suspects involvement of PPAR-γ in gastric carcinogenesis

EPIX Pharmaceuticals' PRX-00023 Therapeutics CNS program in Phase 2B/3 offered for auction sale

HealthCore study reports that oral controllers provide better clinical outcomes for asthma patients

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Dynavax announces European development strategy for investigational adult hepatitis B vaccine in Europe

Tiotropium - corticosteroid combination improves lung disease survival

Discovery of new molecular pathway for targeting cancer

Discovery of genetic markers to help fight diabetes

Being overweight or obese does not worsen asthma, but may reduce response to medications

Merck Serono starts second phase III trial of Safinamide in advanced Parkinson's

Ferring Pharmaceuticals launches new trial of Degarelix for intermittent androgen deprivation therapy

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News